A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance

黄褐斑 医学 皮肤病科 养生 色素沉着 随机对照试验 安慰剂 外科 病理 替代医学
作者
Manas Chatterjee,Shekhar Neema,Gopalsing Rameshsing Rajput
出处
期刊:Indian Journal of Dermatology, Venereology and Leprology [Medknow]
卷期号:88: 51-58 被引量:2
标识
DOI:10.25259/ijdvl_976_18
摘要

Melasma is the commonest cause of facial hypermelanosis in skin type IV-VI. First-line treatment includes a triple combination containing topical corticosteroid and hydroquinone which have side effects on prolonged use. Chemical peels are a second-line management option with the laser being used in refractory cases, but the worsening of hyperpigmentation in darker skin types can occur following laser therapy. Sunscreen is a must to prevent relapses.(i) To compare the effects of treatment with a proprietary combination (phenyl ethyl resorcinol, nonapeptide-1, aminoethyl phosphinic acid, antioxidants and sunscreen) versus sunscreen alone in limiting or reducing, melasma and preventing recurrence as a maintenance regimen after the initial use of triple combination,(ii) to evaluate the safety of the formulation studied, and (iii) to study the improvement of the quality of life of the patients after using the study formulation versus placebo.It was a prospective double-blinded parallel-group randomized controlled pilot study. A total of 46 subjects were recruited by consecutive sampling methods and randomized to 23 each in case and control groups. The study period was eight months with three phases. Phase 1 constituted the application of triple combination for eight weeks by both groups followed by phase 2 with the case group applying proprietary medicine and the control group applying sunscreen. Phase 3 was a follow-up period to see the sustenance of results in both groups as well as any evidence of relapses. Sunscreen was applied in all three phases.Case group in the study showed improvement in the melasma severity score and mean melanin index as measured by mexameter but it did not attain statistical significance as compared to the control group. The melasma area and severity index score showed a consistent reduction in the case group, whereas it increased in the control group from baseline.Small sample size and a short follow-up period of our study were major limitations.The proprietary combination, which has sunscreen as one of its constituents, is more effective in maintaining remission after triple combination without any added inconvenience of application of two separate preparations as compared to sunscreen alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
领导范儿应助威武的元冬采纳,获得30
4秒前
4秒前
junjun2011完成签到,获得积分10
6秒前
Dasha完成签到,获得积分10
6秒前
充电宝应助puzi采纳,获得10
8秒前
LiuLiu发布了新的文献求助10
9秒前
深情安青应助昏睡的绿海采纳,获得10
9秒前
10秒前
大大的西瓜完成签到 ,获得积分10
14秒前
华仔应助XYN1采纳,获得10
15秒前
15秒前
A阿澍发布了新的文献求助30
15秒前
丘比特应助TMX采纳,获得10
17秒前
19秒前
量子星尘发布了新的文献求助10
20秒前
22秒前
无奈满天发布了新的文献求助10
25秒前
25秒前
25秒前
26秒前
27秒前
28秒前
zhou269完成签到,获得积分10
30秒前
在逃公主许翠花完成签到,获得积分10
30秒前
littleblack发布了新的文献求助10
31秒前
TMX发布了新的文献求助10
31秒前
31秒前
DaiTing发布了新的文献求助10
31秒前
32秒前
简单点发布了新的文献求助10
32秒前
华仔应助无奈满天采纳,获得10
32秒前
fjejj发布了新的文献求助10
33秒前
sisi发布了新的文献求助10
34秒前
华仔完成签到,获得积分10
36秒前
华仔应助特梅头采纳,获得10
38秒前
39秒前
无奈满天完成签到,获得积分10
40秒前
yyuu完成签到,获得积分10
43秒前
44秒前
45秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988920
求助须知:如何正确求助?哪些是违规求助? 3531290
关于积分的说明 11253247
捐赠科研通 3269903
什么是DOI,文献DOI怎么找? 1804830
邀请新用户注册赠送积分活动 882027
科研通“疑难数据库(出版商)”最低求助积分说明 809052